Abatacept, Anakinra, Adalimumab, Etanercept, Infliximab, Rituximab
Noted RheumatologyRestrictedLater-line line
Treatment of severe, active rheumatoid arthritis in patients who have failed to respond to non-biological disease-modifying antirheumatic drugs (DMARDs).
1
Submissions
1 resub
2009–09
On the record
—
ICER range
Not modelled
Cost basis
Access path
- Dec 2009Noted
vs Mixed Treatment Comparisons of biological DMARDs; control…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Economic model developed but ICER values not explicitly stated in the public summary document. The document discusses a semi-Markov model and scenario analyses but does not publish specific ICER figures.
The PBAC noted that the continuation rates for rituximab and abatacept were lower than for the other agents, and agreed that these lower continuation rates were likely due to these being the last two drugs listed on the PBS but could also reflect that these drugs may be used in more treatment resistant patients. PBAC · 2009
Decision context
PopulationPatients with severe, active rheumatoid arthritis who have failed to respond to non-biological disease-modifying antirheumatic drugs (DMARDs), with specific restrictions on sequencing of biological agents based on PBS subsidy arrangements.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Dec 2009 | Noted | Mixed Treatment Comparisons of biological DMARDs; control groups in randomised controlled trials | — | Meta-analysis · ACR20 |